Cochrane · systematic review · CD006910
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
Newhouse, R, Nelissen, E, El-Shakankery, KH, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
19
No studies
2
Included studies
NR
No studies 2 · 9.5%Ungraded 0 · 0%Very low 7 · 33.3%Low 3 · 14.3%Moderate 9 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings 1: PLD with chemotherapy compared to alternative combination chemotherapy in recurrent platinum‐sensitive EOC
Population: adult women with recurrent platinum‐sensitive EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | HR 0.93 [0.83, 1.04] | 5 studies · 2006 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Progression‐free survival (PFS) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | HR 0.81 [0.74, 0.89] | 5 studies · 2006 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Quality of life (QoL) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | no estimate extracted | 1 study · 608 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Overall severe adverse events (grade ≥ 3) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | RR 1.11 [0.95, 1.3] | 2 studies · 834 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Anaemia (grade ≥ 3) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | RR 1.37 [1.02, 1.85] | 5 studies · 1961 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Hand‐foot syndrome (grade ≥ 3) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | RR 4.01 [1, 16.01] | 2 studies · 1028 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Neurological (grade ≥ 3) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | RR 0.38 [0.2, 0.74] | 4 studies · 1900 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Summary of findings 2: PLD alone compared to other conventional chemotherapy in recurrent platinum‐resistant EOC
Population: adult women with recurrent platinum‐resistant EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Summary of findings 2: PLD alone vs other conventional chemotherapy | HR 0.96 [0.77, 1.19] | 6 studies · 1995 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Progression‐free survival (PFS) Summary of findings 2: PLD alone vs other conventional chemotherapy | HR 0.94 [0.85, 1.04] | 4 studies · 1803 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Quality of life Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | NR | No studies |
Overall severe adverse events (grade > 3) Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | 2 studies · 964 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Anaemia (grade ≥ 3) Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | 5 studies · 1968 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Hand‐foot syndrome (grade ≥ 3) Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | 6 studies · 2184 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Neurological (grade ≥ 3) Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | 3 studies · 1222 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Summary of findings 3: PLD with chemotherapy compared to PLD alone in recurrent platinum‐resistant epithelial ovarian cancer
Population: adult women with recurrent platinum‐resistant epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Summary of findings 3: PLD with chemotherapy vs PLD alone | HR 0.92 [0.7, 1.21] | 1 study · 242 participants | Moderate Downgraded: risk of bias, imprecision |
Progression‐free survival (PFS) Summary of findings 3: PLD with chemotherapy vs PLD alone | HR 0.94 [0.73, 1.22] | 2 studies · 353 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Summary of findings 3: PLD with chemotherapy vs PLD alone | no estimate extracted | NR | No studies |
Overall severe adverse events (grade ≥ 3) Summary of findings 3: PLD with chemotherapy vs PLD alone | RR 2.48 [1.98, 3.09] | 1 study · 663 participants | Moderate Downgraded: risk of bias, imprecision |
Anaemia (grade ≥ 3) Summary of findings 3: PLD with chemotherapy vs PLD alone | RR 2.38 [1.46, 3.87] | 2 studies · 785 participants | Moderate Downgraded: risk of bias, imprecision |
Hand‐foot syndrome (grade ≥ 3) Summary of findings 3: PLD with chemotherapy vs PLD alone | RR 0.24 [0.14, 0.4] | 2 studies · 785 participants | Moderate Downgraded: risk of bias, imprecision |
Neurological (grade ≥ 3) Summary of findings 3: PLD with chemotherapy vs PLD alone | RR 1.4 [0.85, 2.31] | 1 study · 663 participants | Low Downgraded: risk of bias, imprecision |